Amgen Files NDA For I.V. Rival To Sensipar
This article was originally published in The Pink Sheet Daily
Executive Summary
The calcimimetic etelcalcetide could be administered intravenously following dialysis sessions for chronic kidney disease patients with secondary hyperparathyroidism, eliminating the high pill burden associated with Sensipar.
You may also be interested in...
Amgen Gets Parsabiv CRL, Gives No Clues As To Why
FDA issued a complete response letter for the Sensipar follow-on, and Amgen declined to provide any details about the reason why or timeline for resubmission.
Amgen Planned Acquisition Of KAI Would Bring In Replacement For Sensipar
Amgen will get KAI’s late-stage-ready asset for a small upfront price and gives itself a logical line extension to its chronic kidney disease drug Sensipar.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.